Dyadic International, Inc. (operating as Dyadic Applied BioSolutions), a US-based biotechnology innovator, has appointed international business development consultancy Intralink to expand its commercial presence in Japan and South Korea — two of Asia’s fastest-growing and most advanced biopharmaceutical markets.

Headquartered in Florida, Dyadic develops precision-engineered, animal-free proteins and enzymes for applications in life sciences, food and nutrition, and industrial sectors. The company aims to scale access to two key products in the region — DNase 1 (RNase free), an enzyme used in biologics and mRNA manufacturing, and Human Transferrin, a recombinant version of transferrin widely used in cell culture media and biopharmaceutical production.

Intralink, operating from 27 global locations, will leverage its life sciences teams in Tokyo and Seoul to identify and engage strategic partners, distributors, and contract development and manufacturing organizations (CDMOs) for Dyadic’s portfolio. The partnership seeks to build direct supply relationships and licensing opportunities in both countries.

The collaboration aligns with regional growth trends in biologics and cell and gene therapy, as Japan and South Korea invest in animal-origin-free manufacturing systems. Both companies expect the initiative to accelerate Dyadic’s commercial momentum in Asia’s evolving biotech landscape.